The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired

About Primm Pharma

Primm Pharma is a Milan, Italy-based company specialized in the development and production of pharmaceutical formulations for slow release injections. Primm Pharma has a portfolio currently consisting of five slow release biogeneric candidates. The lead product Spherotide will primarily be used for the treatment of prostate cancer and endometriosis and will be available in emerging markets from mid 2017.

Primm Pharma Headquarters Location



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Primm Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Primm Pharma is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Latest Primm Pharma News

Xbrane divests Primm Pharma

Feb 24, 2021

Xbrane divests Primm Pharma Xbrane Biopharma has entered into a non-binding term-sheet with NewFaDem for a divestment of Primm Pharma. Xbrane’s long term focus is to become a world leading biosimilar developer, and hence Primm Pharma falls outside its strategic scope, the company states. A total consideration of up to €14 million The non-binding terms include the sale of 100% of the shares in Primm Pharma to NewFaDem for a total consideration of up to €14 million to be paid in part upfront and on development and sales related milestones. Primm Pharma is a fully owned subsidiary of Xbrane located in Italy and specialized in the development of long acting injectables based on a microsphere encapsulation technology. Primm Pharma´s lead product candidate is Spherotide, a long acting triptorelin formulation, intended to become the first approved generic to Decapeptyl with global annual sales of approximately € 400 million. The next step in the development of Spherotide is to initiate the phase III trial and proceed towards filing in Europe. Xbrane and NewFaDem jointly target to complete the transaction during 2021, after a confirmatory due diligence has taken place. Photo of Martin Åmark, CEO, Xbrane

  • Where is Primm Pharma's headquarters?

    Primm Pharma's headquarters is located at Milan.

  • What is Primm Pharma's latest funding round?

    Primm Pharma's latest funding round is Acquired.

  • Who are the investors of Primm Pharma?

    Investors of Primm Pharma include Xbrane Biopharma.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.